Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Lupin Inc. is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed between 2 distinct examiners and 2 distinct art units. This indicates a high level of concentration, with a small number of individuals and units handling the company's active portfolio.
The busiest examiner for the portfolio is MERCIER, MELISSA S, who is currently overseeing 2 pending office actions. This means that a majority of the company's active workload is centralized under a particular individual. For a practitioner, this provides a significant opportunity to develop a consistent negotiation strategy and build a strong rapport with this primary examiner.
The involvement of 2 distinct art units for 3 pending office actions suggests that the technical focus is narrow. However, because MERCIER, MELISSA S handles the majority of the workload, her influence is dominant across the portfolio. Practitioners should prioritize the requirements of the busiest examiner, as her decisions will impact most of the active matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MERCIER, MELISSA S | 2 | 72.1% | +5.8% |
| BOUCHELLE, LAURA A | 1 | 80.2% | +10.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17983478 | Applicator for Implant Insertion | BOUCHELLE, LAURA A | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17983478 | Applicator for Implant Insertion | BOUCHELLE, LAURA A | 28d |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18391538 | DRUG DELIVERY SYSTEM FOR ULTRA-LOW DOSE ESTROGEN COMBINATIONS AND METHODS AND USES THEREOF | MERCIER, MELISSA S | 1615 | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18240284 | DRUG DELIVERY SYSTEM FOR ULTRA-LOW DOSE ESTROGEN COMBINATIONS AND METHODS AND USES THEREOF | MERCIER, MELISSA S | 1615 | §103DP | Non-Final OA | 27d | Pending | Aug 30, 2023 |
| 17983478 | Applicator for Implant Insertion | BOUCHELLE, LAURA A | 3783 | §103 | Non-Final OA | 28d | Pending | Nov 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLupin Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Melissa S Mercier has the most, with 2 of Lupin Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
